Update on Cardiovascular Prevention and Cardiac Rehabilitation;Temas de actualidad en prevención cardiovascular y rehabilitación cardiaca

Revista Espanola de Cardiologia Suplementos

Volumn 9, Issue 1, 2009, Pages 4-13

  León Latre, Montserrat ^a   Mazón Ramos, Pilar ^b   Marcos, Esther ^c   García Porrero, Esteban ^d  

^a INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL DE LEÓN   (Spain)

Author keywords

Cardiac rehabilitation; Cardiovascular disease prevention; Cardiovascular risk; Exercise training; Metabolic syndrome

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; RIMONABANT;

ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD CHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC DIET; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART INFARCTION; HEART REHABILITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PRIMARY PREVENTION; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT;

EID: 67651033975     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1131-3587(09)71768-6     Document Type: Article

References (41)

1. Cohn J.N., and Duprez D.A. Time to foster a racional approach to preventing cardiovascular morbid events. J Am Coll Cardiol 52 (2008) 327-329
2. Greenland P., and Lloyd-Jones D. Defining a rational approach to screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 52 (2008) 330-332
3. Graham I., Atar D., Borch-Jonhsen K., Boysen G., Burell G., Cifkova R., et al. Guías europeas sobre prevención cardiovascular en la práctica clínica: versión resumida. Rev Esp Cardiol 61 (2008) 82.e1-82.e49
4. Ponn M., Rubin G.D., Achenbach S., Attebery T.W., Berman D.S., Brady T.J., et al. Consensus update on the appropriate usage of cardiac computed tomographic angiography. J Inv Cardiol 19 (2007) 484-490
5. Naghavi M., Falk E., Hecht H.S., Jamieson M.J., Kaul S., Berman D., et al., SHAPE Task Force. From vulnerable plaque to vulnerable patient. Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE). Am J Cardiol 98 (2006) H2-H15
6. Schroeder S., Achenbach S., Bengel F., Burstahler C., Cademartiri F., De Feyter P., et al. Cardiac computed tomography: indications, applications, limitations, and training requirements. Report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardilogy. Eur Heart J 29 (2008) 531-556
7. Oudkerk M., Stillman A.E., Halliburton S., Kalender W., Möhlenkamp S., McCollough C., et al. Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging. Int J Cardiovasc Imaging 24 (2008) 645-671
8. Bluemke D.A., Achenbach S., Budoff M., Gerber T.C., Gersh B., Hillis D., et al. Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention of the Council on Cardiovascular Radiology and Intervention and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young. Circulation 118 (2008) 586-606
9. Choi E.K., Choi S., Rivera J.J., Nasir K., Chang S.A., Chun E.J., et al. Coronary Computed Tomography Angiography as a Screening Tool for the Detection of Occult Coronary Artery Disease in Asymptomatic Individuals. J Am Coll Cardiol 52 (2008) 357-365
10. De Feyter P.M., and Schultz C.J. Computed tomography coronary angiography for screening asymptomatic subjects. A bridge too far?. J Am Coll Cardiol 52 (2008) 366-368
11. Hassain P., Kawar B., and El Nabas M. Obesity and diabetes in developing world: a growing chalenge. N Engl Med 352 (2007) 213-216
12. Otero F., Grigorian L., Lado M., Lado A., Turrado V., Santos J.A., et al. Asociación entre hipertensión refractaria y riesgo cardiometabólico. Estudio HIPERFRE. Nefrología 28 (2008) 425-432
13. Lambert M., Delvin E.E., Levy E., O'Laughlin J., Paradis G., Barnett T., et al. Prevalence of cardiometabolic risk factors by weight status a population based simple of Québec children and adolescents. Can J Cardiol 24 (2008) 575-583
14. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31 (2008) 811-822
15. Grundy S.M. A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor. Eur Herth J Suppl 10 (2008) B16-B23
16. Gustafson B., Hammarstedt A., Andersson C.X., and Smith U. Inflammed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 2276-2283
17. Ouchi N., Shibata R., and Waish K. Cardioprotection by adiponectin. Trends Cardiovasc Med 16 (2006) 141-146
18. Barnett A.H. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes. Diabetes Vas Dis Res 5 (2008) 9-14
19. De Luca C., and Olefsky J.M. Inflammation and insulin resistance. FEBS Lett 582 (2007) 97-105
20. Glund S., Deshmukh A., Long Y.C., Moller T., Koistinen H.A., Caidahl K., et al. Iterleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56 (2007) 1630-1637
21. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.G., Liu F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57 (2008) 1246-1253
22. Ferrannini E., Sironi A.M., Lozzo P., and Gastaldelli A. Intra-abdominal adiposity, abdominal obesity and cardiometabolic risk. Eur Hearth J Suppl 10 (2008) B4-B10
23. Pollin I.S., Brian G., Shattuck T., Sadler M.D., Boyle J.R., McKillop, et al. High prevalence of cardiometabolic risk factors in women considered low risk by traditional risk assessment. J Womens Health (Larchmt) 17 (2008) 947-953
24. Alegría E., Castellano J.M., and Alegría A. Obesidad, síndrome metabólico y actuación terapéutica. Rev Esp Cardiol 61 (2008) 752-764
25. Barnett A.H. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes. Diabetes Vasc Dis Res 5 (2008) 9-14
26. Meaney E., Vela A., Samaniego V., Meaney A., Asbun J., Zempoalteca J.C., et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol 35 (2008) 895-903
27. Nieuwdorp M., Stoes E.S.G., Kastelein J.J., and Fenofibrate/Metformin Study Group. Normalization of metabolic syndrome using fenofibrate, metformin or their combination. Diabetes Obes Metab 9 (2007) 869-878
28. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holma R.R., Sherwin R., et al. Managment of hyperglycemia in type 2 diabetes: A consenst algorithm for the initiation and anjustment of therapy. Update regarding thiazolidinediones: a consensus statement from the American diabetes Association and the European Association for the Study of diabetes. Diabetes Care 31 (2008) 173-175
29. Gisberg N.H., Bonds D.E., Lovato L.C., Crouse J.R., Elam M.B., Linz P.E., et al. Evolution of the lipid trial protocol of the Action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol 99 (2007) I56-I67
30. Rana J.S., Nieuwdorp M., Jukema J.W., and Kastelein J.J.P. Cardiovascular metabolic syndrome: an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diab Obes Metab 9 (2007) 218-232
31. Van Gaal L., Pi-Sunyer X., Después J.P., McCarthy C., and Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 (2008) S229-S240
32. Alegría E., Cordero A., Laclaustra M., Grima A., León M., Casasnovas J.A., et al. Prevalencia del síndrome metabólico en población laboral española: registro MESYAS. Rev Esp Cardiol 58 (2005) 797-806
33. Cordero A., Laclaustra M., León M., Grima A., Casasnovas J.A., Luengo E., et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. Am J Hypertension 19 (2006) 189-196
34. Cordero A., Laclaustra M., León M., Casasnovas J.A., Grima A., Nájar M., et al. Factores de riesgo cardiovascular y síndrome metabólico asociados a la disfunción renal subclínica: subanálisis del Registro MESYAS. Med Clin (Barc) 125 (2005) 653-658
35. Laclaustra M., Corella D., and Ordovas J.M. Metabolic syndrome pathophysiology: The role of adipose tissue. Nutr Metab Cardiovasc Dis 28 (2007) 301-320
36. Cordero A., Laclaustra M., León M., Casasnovas J.A., Grima A., Luengo E., et al., On behalf of the MESYAS Registry Investigators. Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am J Cardiol 102 (2008) 424-428
37. Cordero A., Moreno J., Martín A., Nasarre E., Alegría Barrero E., and Alegría Ezquerra E. Prevalencia de síndrome metabólico y asociación con la cardiopatía isquémica en pacientes cardiológicos ambulatorios. Rev Esp Cardiol 206 (2006) 259-265
38. Physical Activity and Public Health: Updated Recommendation for Adults From the American College of Sports Medicine and the American Heart Association Circulation. 2007;116:1081-93.
39. Williams M.A., Haskell W.L., Ades P.A., Amsterdam E.A., Bittner V., Franklin B.A., et al. American Heart Association Council on Clinical Cardiology; American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Resistance Exercise in Individuals With and Without Cardiovascular Disease: Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. 2007 Update: A Scientific Statement From the American Heart Association. Circulation 116 (2007) 572-584
40. Nocon M., Hiemann T., Müller-Riemenschneider F., Thalau F., Roll S., and Willich S.N. Association of physical activity with allcause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil 15 (2008) 239-246
41. Sofi F., Capalbo A., Cesari F., Abbate R., and Gensini G.F. Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur J Cardiovasc Prev Rehabil 15 (2008) 247-257